Your browser doesn't support javascript.
loading
Dynamic Analysis of CA125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer as a Predictor for Platinum Sensitivity.
Pelissier, Aurélie; Bonneau, Claire; Chéreau, Elisabeth; DE LA Motte Rouge, Thibault; Fourchotte, Virginie; Daraï, Emile; Rouzier, Roman.
Afiliación
  • Pelissier A; Department of Breast and Gynecological Surgery, Institut Curie, Paris, France Department of Gynecology-Obstetrics, University Reims Hospital, Reims, France a.komorek@gmail.com.
  • Bonneau C; Department of Breast and Gynecological Surgery, Institut Curie, Paris, France Department of Gynecological Surgery, Tenon Hospital, Paris, France.
  • Chéreau E; Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France.
  • DE LA Motte Rouge T; Department of Oncology, Centre René Huguenin, Institut Curie, Saint Cloud, France.
  • Fourchotte V; Department of Breast and Gynecological Surgery, Institut Curie, Paris, France.
  • Daraï E; Department of Gynecological Surgery, Tenon Hospital, Paris, France.
  • Rouzier R; Department of Breast and Gynecological Surgery, Institut Curie, Paris, France Versailles-St-Quentin-en-Yvelines University, EA 7285: Risques Cliniques et Sécurité en Santé des Femmes et en Santé Périnatale, Montigny-Le-Bretonneux, France.
Anticancer Res ; 36(4): 1865-71, 2016 Apr.
Article en En | MEDLINE | ID: mdl-27069172
AIM: Our objective was to evaluate the kinetic parameters of serum CA125 during neoadjuvant platinum-based chemotherapy (NAC), in patients with epithelial ovarian cancer, in order to identify a surrogate marker of sensitivity to platinum. MATERIALS AND METHODS: Patients diagnosed between 2002 and 2009, and treated with NAC and interval debulking surgery, were included in the study. RESULTS: One hundred and forty-two patients met the study inclusion criteria. Fifty-four patients (38%) were platinum-sensitive (PFI >12 months). A CA125 level after the 3rd NAC cycle <35 UI/ml was significantly associated with improved overall survival (OS) and relapse-free survival (RFS). In the multivariate model, patients with a CA125 level after the 3rd NAC cycle >35 UI/ml were 3.8-times more at risk for PFI <12 months (95% CI=1.7-8.5, p<0.001). CONCLUSION: A CA125 level after the 3rd NAC <35 UI/ml is an independent predictor for tumor platinum-sensitivity.
Asunto(s)
Palabras clave
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Compuestos de Platino / Neoplasias Glandulares y Epiteliales / Antígeno Ca-125 / Proteínas de la Membrana / Antineoplásicos Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Anticancer Res Año: 2016 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Grecia
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Compuestos de Platino / Neoplasias Glandulares y Epiteliales / Antígeno Ca-125 / Proteínas de la Membrana / Antineoplásicos Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Anticancer Res Año: 2016 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Grecia